Financials
- Fiscal year
- 2025
- Total assets
- €689,137
- Loss
- -€142,558
- Solvency
- -42.1%
Total assets▼ 5.1%
Net result
20222025
Apotheek Uilenberg
ActiveSummary
The computed 12-month bankruptcy probability of Apotheek Uilenberg is 1.8% (moderate). The 2025 annual accounts show negative equity (-€289,841) and a net result of -€142,558. Equity is shrinking by ~70.5% per year across the filed fiscal years. Its solvency ranks better than 13% of 20110 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
What they do
Retail sale of pharmaceutical products
NACE 47730
1 site
How big
€689,137total assets 2025
- Staff
- 0.8 FTE
- Equity
- -€289,841
- Loss
- -€142,558
Turnover not published (abridged schema)
Who decides
Accounts 154 d early0 of 1 deed read
Why 52- Loss of €142,558, the second in a row (FY 2025)- Negative equity -€289,841- Sector Retail trade (NACE 47)+ Size: total assets €689,137Show the evidence
Checked score
Score 2025
52
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Better than 10% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2024
Weak
Solvency
0-5
equity -42.1% of total assets
Liquidity
23-19
short-term debt 55.1% · cash 1.1%
Profitability
0-6
return on assets -20.7%
Bankruptcy probability, 12 months
1.8%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
- Size: total assets €689,137 lowers the probability for this profile
- Loss of €142,558, the second in a row (FY 2025) raises the probability
- Negative equity -€289,841 raises the probability
- Sector Retail trade (NACE 47) raises the probability
No credit on open account
Liquidity short (current ratio 0.24 against 0.42 in 2024; short-term debt: 55.1% and cash: 1.1% of total assets), and equity is negative.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 6%, liquidity 21%, profitability 6%, growth against the median 6%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 02-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
22232425
2022 to 2025 · latest year -€289,841
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-02-2026, 154 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
154 d early
2024
162 d early
2023
53 d early
2022
56 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 4 accounts on average 106 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 17 April (3 of the last 4 filed years within 53 days of that day).
Companies Code · seven monthsPosition in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · micro…
- Weakest financial yearnet -€142,558
- Annual accounts filedfiscal year 2024 · micro…
Key points
- Risk: Negative equityfiscal year 2025: debts exceed assets -€289,841 View
- Risk: 4 loss-making years in a rowloss fiscal year 2025 -€142,558 View
- Caution: Result fell in 2025from -€71,671 to -€142,558 ▼ 98.9% View
- Caution: Among the weakest 5% on net resultsector median €5,003 · 20,084 companies -€142,558 View
- Positive: Always filed on timeaccounts within the deadline every year 4 years View
By topic
Timeline
- Events
- 5
- Since
- 2023
- Next accounts
- by 31-07-2027
- 27-02-2026Annual accounts filed
- 31-12-2025Weakest financial year
- 19-02-2025Annual accounts filed
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 05-01-2021
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.